BNGO logo

BNGO
Bionano Genomics Inc

100,913
Mkt Cap
$12.53M
Volume
82,049.00
52W High
$5.50
52W Low
$1.06
PE Ratio
-0.21
BNGO Fundamentals
Price
$1.13
Prev Close
$1.16
Open
$1.14
50D MA
$1.16
Beta
1.67
Avg. Volume
597,698.45
EPS (Annual)
-$4.85
P/B
0.27
Rev/Employee
$293,896.91
$4.31
Loading...
Loading...
News
all
press releases
Bionano Genomics (BNGO) Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·20d ago
News Placeholder
More News
News Placeholder
Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story
Bionano Genomics stock soared on Monday as investors anticipated the company's Q4 earnings report.read more...
Benzinga·20d ago
News Placeholder
United Airlines, AGI And 3 Stocks To Watch Heading Into Monday
US stock futures down, Caledonia Mining, United Airlines & Agi to report earnings, Cheetah Net & BioNano Genomics to release results.read more...
Benzinga·21d ago
News Placeholder
Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Bionano Genomics, Inc. (BNGO) will release Q4 earnings on March 23. Analysts expect $1.40 loss per share on $7.85M revenue. Stock closed at $1.12.read more...
Benzinga·24d ago
News Placeholder
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
Zacks·3mo ago
News Placeholder
iBio, Inc. (IBIO) Reports Q1 Loss
iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +83.78% and +86.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +14.71% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock
Bionano Genomics (BNGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks·7mo ago
News Placeholder
Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Zacks·8mo ago
<
1
2
...
>

Latest BNGO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.